92 reports

  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • GENETIC DISORDERS, PROGRESSION OF CF

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease Summary Genetic disorders are caused by abnormalities in a person’s genome and represent...

  • Genetic Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Demand
  • Genetic diseases
  • Non-genetic diseases

About Prenatal DNA Sequencing Prenatal DNA sequencing is the method of DNA sequencing where DNA isolated from the blood of pregnant women to reveal the full genetic code of a fetus. It is useful in detecting disorders such as Down syndrome, cystic fibrosis, thalassemia, and cancer. Technavio’s analysts forecast...

  • Genetic Disorder
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Natera, Inc.

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the US NAT market.

  • Genetic Disorder
  • Pathology
  • United States
  • Demand
  • Forecast

2018 Japan Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Japanese NAT

  • Genetic Disorder
  • Pathology
  • Japan
  • Demand
  • Forecast

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the UK NAT market.

  • Genetic Disorder
  • Pathology
  • United Kingdom
  • Demand
  • Forecast

2018 Italy Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Italian NAT

  • Genetic Disorder
  • Pathology
  • Italy
  • Demand
  • Forecast

2018 Germany Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the German NA

  • Genetic Disorder
  • Pathology
  • Germany
  • Demand
  • Forecast

2018 Spain Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Spanish NAT

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand
  • Forecast

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Molecular Diagnostic
  • Spain
  • Demand
  • Forecast
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The increasing...

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022
  • 1.1 DEFINITION

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 1.1 DEFINITION
  • 5 Cystic Fibrosis Market, By Treatment Method

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Cystic fibrosis is a rare genetic disorder caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. It largely affects the lungs and digestive system, and causes the secretions to become thick and sticky. The individuals with cystic fibrosis develop lung disease, resulting...

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Clinical Trials by E7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials

Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015" provides an overview of Primary Immune Deficiency (PID) clinical trials scenario. This report provides top line data relating to the...

  • Genetic Disorder
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

(USA) ##.

  • Genetic Disorder
  • Pharmaceutical
  • China
  • World
  • Market Shares
  • INTRODUCTION

IT IS AN AUTOSOMAL RECESSIVE GENETIC disorder caused by mutations in the CF gene.

  • Genetic Disorder
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast
  • Snapshot of Cystic Fibrosis
  • 06. Introduction

About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic...

  • Genetic Disorder
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • 7.3 GENETIC DISORDERS
  • VIRAL VECTOR MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2016-2023 (USD MILLION)

The global viral vector manufacturing market is projected to grow at a CAGR of 20.0%. The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%. The growth of this market is expected to be driven by rising prevalence of target diseases and disorders,...

  • Genetic Disorder
  • Viral Vector
  • North America
  • United States
  • Market Size

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • Proportion of Turner Syndrome to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

Turner Syndrome Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Turner Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Turner Syndrome clinical trials scenario.This report provides top line data relating to the clinical trials on Turner...

  • Genetic Disorder
  • Growth Hormone
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • Proportion of Tuberous Sclerosis to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*

Tuberous Sclerosis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Tuberous Sclerosis Global Clinical Trials Review, H2, 2018" provides an overview of Tuberous Sclerosis clinical trials scenario.This report provides top line data relating to the clinical trials...

  • Genetic Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • Novartis AG
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2018" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario.This report provides top line data...

  • Antiviral
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

Spinocerebellar Ataxia (SCA) Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Spinocerebellar Ataxia (SCA) Global Clinical Trials Review, H2, 2018" provides an overview of Spinocerebellar Ataxia (SCA) clinical trials scenario.This report provides top line data...

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Kissei Pharmaceutical Co., Ltd.
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

Urea Cycle Disorders Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Urea Cycle Disorders Global Clinical Trials Review, H2, 2018" provides an overview of Urea Cycle Disorders clinical trials scenario.This report provides top line data relating to the clinical...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Horizon Pharma plc
  • PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2018" provides an overview of Adrenoleukodystrophy...

  • Genetic Disorder
  • Monoclonal Antibody
  • Neurological Disorder
  • World
  • Product Initiative
  • Proportion of Severe Combined Immune Deficiency (SCID) to Genetic Disorders Clinical Trials, G7 Countries (%),
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS

Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018" provides an overview of Severe Combined Immune Deficiency (SCID) clinical trials scenario.This...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • GlaxoSmithKline plc